Elite Pharmaceuticals files ANDA for generic anticoagulant drug
Elite Pharmaceuticals submitted an Abbreviated New Drug Application to the FDA for a generic anticoagulant product in a $26 billion market with no current generic competition. Approval depends on FDA clearance and addressing unexpired patents and exclusivities of the branded product.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day